news
SARS-CoV-2 papain-like protease could be a novel drug target
Scientists suggest targeting the SARS-CoV-2 papain-like protease (PLpro) with inhibitors could prevent the spread of infection.
List view / Grid view
Coronavirus
news
Targeting host proteins could lead to pan-coronavirus antivirals
Researchers suggest that targeting host proteins with drugs, rather than directly targeting enzymes or proteins on SARS-CoV-2 and related coronaviruses, could improve outcomes.
news
SARS-CoV-2-targeting antibodies persist for at least three months in COVID-19 patients
Two separate studies show that IgG serotype antibodies targeting the SARS-CoV-2 spike protein are still detectable in patient’s blood and saliva after 90 days.
![Syringe drawing liquid from a vial labelled 'REMDESIVIR', on a background of abstract SARS-CoV-2 particles [Credit: ffikretow@hotmail.com / Shutterstock.com].](https://drug.russellpublishing.co.uk/wp-content/uploads/remdesivir-SARS-CoV-2-750x500.jpg)
![Syringe drawing liquid from a vial labelled 'REMDESIVIR', on a background of abstract SARS-CoV-2 particles [Credit: ffikretow@hotmail.com / Shutterstock.com].](https://drug.russellpublishing.co.uk/wp-content/uploads/remdesivir-SARS-CoV-2-scaled-e1602154798857.jpg)
news
Researchers identify a potential remdesivir resistance mechanism in SARS-CoV-2
Exploring how the Ebola virus develops remdesivir resistance has highlighted a mutation that could allow SARS-CoV-2 to do the same.
news
Build-up in the lungs could be targeted by future severe COVID-19 treatments
Breaking down or slowing the production of a hyaluronan jelly which builds up in the lungs of some severe COVID-19 patients could reduce respiratory distress and prevent death.
news
Approved MS medication inhibits SARS-CoV-2 replication in vitro
Dimethyl fumarate (DMF), a multiple sclerosis (MS) drug, inhibited SARS-CoV-2 replication and the hyper-inflammatory immune response associated with COVID-19.
news
The NF-κB pathway drives fatal inflammation in COVID-19, say scientists
Researchers found that the SARS-CoV-2 infection activates the NF-κB pathway, driving unchecked inflammation that contributes to total organ failure in COVID-19 patients.
news
Novel RNA-targeting molecule can halt SARS-CoV-2 replication
The C5 compound targets the frameshifting element that allows SARS-CoV-2 to effectively replicate and marks the genome for destruction to stop the infection spreading.
news
Could a sphingosine nasal spray prevent COVID-19?
According to a study, the lipid sphingosine can inhibit SARS-CoV-2 infection and could potentially be delivered in a nasal spray to prevent COVID-19 infections.
news
Why do some patients develop COVID-19 pneumonia?
Scientists reveal that some patients who develop severe COVID-19 symptoms mount ineffective immune responses due to a lack of type I interferons, either through genetic mutation or inactivation by auto-reactive antibodies.
news
Experimental antiviral AR-12 could be a promising COVID-19 treatment
Scientists have demonstrated that AR-12 can inhibit SARS-CoV-2 replication and are working to initiate clinical trials evaluating the antiviral drug.
news
4-PBA could prevent cytokine storm in severe COVID-19
Scientists explore whether the anti-stress drug, 4-Phenylbutiric acid (4-PBA), could prevent cytokine storms causing respiratory failure in COVID-19 patients.
news
Novel pseudo-virion probes to study SARS-CoV-2 viral entry
The non-infectious quantum dot probes are designed to enable researchers to safely study interactions between the SARS-CoV-2 Spike (S) protein and human cells.
news
Could FDA-approved drug heparin prevent SARS-CoV-2 infection?
SARS-CoV-2 entry into human cells is dependent on heparan sulfate and disrupting this interaction using heparin reduces infectivity of the coronavirus, find scientists.
news
Tiny antibody component could treat or prevent SARS-CoV-2
The component, now developed into a drug called Ab8, was highly effective at treating and preventing SARS-CoV-2 infection in animal models.
